Cargando…

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer

BACKGROUND: Prostate-specific membrane antigen (PSMA) imaging has been suggested as highly sensitive modality for detection of metastases in patients with biochemically recurrent or advanced prostate cancer (PCa). PSMA expression is associated with grade and stage and has a relationship with androge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vlachostergios, Panagiotis J., Niaz, Muhammad Junaid, Sun, Michael, Mosallaie, Seyed Ali, Thomas, Charlene, Christos, Paul J., Osborne, Joseph R., Molina, Ana M., Nanus, David M., Bander, Neil H., Tagawa, Scott T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930491/ https://www.ncbi.nlm.nih.gov/pubmed/33680970 http://dx.doi.org/10.3389/fonc.2021.630589

Ejemplares similares

Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer
por: Tagawa, Scott T., et al.
Publicado: (2013)

Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Review of Lutetium-177-labeled Anti-prostate-specific Membrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic Castration-resistant Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Biomarkers in Prostate-Specific Membrane Antigen Theranostics
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Sun, Michael, et al.
Publicado: (2020)

Targeting Neuroendocrine Prostate Cancer: Molecular and Clinical Perspectives
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2015)

Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer
por: Perera, Mahasha P.J., et al.
Publicado: (2022)

Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer
por: Lunger, Lukas, et al.
Publicado: (2021)

The Role of the Small Ubiquitin-Related Modifier (SUMO) Pathway in Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2012)

ERG induces taxane resistance in castration-resistant prostate cancer
por: Galletti, Giuseppe, et al.
Publicado: (2014)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
por: Mizokami, Atsushi, et al.
Publicado: (2017)

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2021)

Divergent clonal evolution of castration resistant neuroendocrine prostate cancer
por: Beltran, Himisha, et al.
Publicado: (2016)

Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration
por: Freedland, Stephen J., et al.
Publicado: (2021)

Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis
por: Mohammadzadeh, Mohammad, et al.
Publicado: (2018)

Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2022)

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
por: Schiff, Joshua P., et al.
Publicado: (2019)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians
por: Sureka, Sanjoy Kumar, et al.
Publicado: (2016)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics
por: Brady-Nicholls, Renee, et al.
Publicado: (2021)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual Evaluations
por: Burgard, Caroline, et al.
Publicado: (2023)

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited
por: Deek, Matthew P., et al.
Publicado: (2021)

Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
por: Lin, Ting-Ting, et al.
Publicado: (2019)

Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study
por: Calderoni, Letizia, et al.
Publicado: (2023)

Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience
por: Maman, Adem
Publicado: (2023)

Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2020)

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022)

Circulating Tumor Cells from Prostate Cancer Patients Interact with E-Selectin under Physiologic Blood Flow
por: Gakhar, Gunjan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rdr4pg2ea8kfs7q5n37m4jo2ck